Subject to change.
Subject to change.
Cheng Cui, Senior Translational Regulatory Affairs Director, brings more than ten years of FDA and industry experience, focusing on digital and computational pathology, biomarkers, companion diagnostics and digital health. At the FDA, he served as lead reviewer for digital and computational pathology devices. At AstraZeneca, he leads translational regulatory strategy for AI-enabled computational pathology and developing biomarkers to accelerate precision oncology.